Health-Related Quality of Life and Disease-Specific Symptoms Among Persons with Thyroid Cancer After Surgery in Yunnan Province, the People’s Republic of China

Rui  Fan; Suparat  Wangsrikhun; Achara  Sukonthasarn

Authors

Rui Fan Kunming Medical University, China
Suparat Wangsrikhun Faculty of Nursing, Chiang Mai University, Thailand https://orcid.org/0000-0002-7379-7693
Achara Sukonthasarn Faculty of Nursing, Chiang Mai University, Thailand https://orcid.org/0000-0001-7569-9563

Keywords:

health-related quality of life, quality of life, symptoms, thyroid cancer

Abstract

OBJECTIVE To examine health-related quality of life (HRQOL), disease-specific symptoms, and relationships between HRQOL and disease-specific symptoms among thyroid cancer patients after surgery in Yunnan Province, the People’s Republic of China.
METHODS Participants in this cross-sectional study included 333 persons with thyroid cancer after surgery receiving care at the First Affiliated Hospital of Kunming Medical University. The HRQOL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire. The Thyroid Cancer Specific HRQOL questionnaire was used to measure the disease-specific symptoms.
RESULTS The mean global health score was 75.00 + 17.09. The mean score of role, social, physical, cognitive, and emotional function were 95.10±14.32, 92.67±16.12, 92.00±8.94, 82.83±16.15 and 81.11±16.47, respectively. The top three disease-specific symptoms experienced by thyroid cancer patients after surgery were psychological symptoms (18.74±17.16), problems with scars (17.77±24.18) and throat/mouth symptoms (17.07±16.64). There were statistically significant negative correlations between dimensions of disease-specific symptoms and dimensions of HRQOL.
CONCLUSIONS This study revealed negative relationships between HRQOL and disease-specific symptoms experienced by thyroid cancer patients after surgery. Health care providers caring for thyroid cancer patients, especially those in China, could use these findings as a basis for further enhancing the quality of care for patients with thyroid cancer after surgery.

References

Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiology. 2013;2013:1-10.

Deng Y, Li H, Wang M, Li N, Tian T, Wu Y, et al. Global burden of thyroid cancer from 1990 to 2017. JAMA Netw Open. 2020;3:e208759.

Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, et al. Cancer incidence and mortality in China, 2014. Chinese J Cancer Res. 2018;30:1-12.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thy-roid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and dif-ferentiated thyroid cancer. Thyroid. 2016;26:1-133.

Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet. 2016;388:2783-95.

Biondi B, Cooper DS. Thyroid Hormone Suppres-sion Therapy. Endocrinol Metab Clin North Am. 2019;48:227-37.

Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocr Metab. 2001;86:1447-63.

Husson O, Haak HR, Buffart LM, Nieuwlaat WA, Oranje WA, Mols F, et al. Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the popu-lation-based PROFILES registry. Acta Oncol. 2013; 52:249-58.

Lee YS, Nam K-H, Chung WY, Chang H-S, Park CS. Postoperative complications of thyroid cancer in a single center experience. J Korean Med Sci. 2010; 25:541.

Van Nostrand D. Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis. 2011;17:154-61.

Bilezikian JP, Khan A, Potts Jr JT, Brandi ML, Clarke BL, Shoback D, et al. Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and chal-lenges for future research. J Bone Miner Res. 2011; 26:2317-37.

Huang SM, Lee CH, Chien LY, Liu HE, Tai CJ. Postoperative quality of life among patients with thyroid cancer. J Adv Nurs. 2004;47:492-99.

Rogers S, Mepani V, Jackson S, Lowe D. Health-related quality of life, fear of recurrence, and emo-tional distress in patients treated for thyroid cancer. Brit J Oral Max Surg. 2017;55:666-73.

Aaronson NK. Quality of life: what is it How should it be measured? Oncology. 1988;2:69-76.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organiza-tion for Research and Treatment of Cancer QLQ- C30: a quality-of-life instrument for use in inter-national clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.

Wan C, Meng Q, Yang Z, Tu X, Feng C, Tang X, et al. Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Annals of Oncology. 2018;19:2053-60.

Husson O, Haak HR, Mols F, Nieuwenhuijzen GA, Nieuwlaat W-A, Reemst PH, et al. Development of a disease-specific health-related quality of life questionnaire (THYCA-QoL) for thyroid cancer survivors. Acta oncol. 2013;52:447-54.

Liu J, Gao J, Tang Y, Wu C, Jiang X, Lao Q, et al. Reliability and validity of Chinese version of thyroid cancer-specific quality of life (THYCA-QOL) ques-tionnaire. Tumor. 2019;39:178-87.

Büttner M, Hinz A, Singer S, Musholt TJ. Quality of life of patients more than 1 year after surgery for thyroid cancer. Hormones. 2020;19:233-43.

Mols F, Schoormans D, Smit JW, Netea-Maier RT, Links TP, van der Graaf WT, et al. Age-related dif-ferences in health-related quality of life among thyroid cancer survivors compared with a norma-tive sample: Results from the PROFILES Registry. Head Neck. 2018;40:2235-45.

Razavi Ratki SK, Fallahi B, Namiranian N, Emami-Ardekani A, Saghari M, Mirabzadeh A, et al. Factors affecting the quality of life of well-differentiated thyroid carcinoma patients: a cross- sectional study on 435 Iranian patients. Iran J Nucl Med. 2016;24:92-98.

Gou J, Cheng W, Lei J, Pan Q, You W, Cai M, et al. Health-related quality-of-life assessment in sur-gical patients with papillary thyroid carcinoma: a single-center analysis from Mainland China. Medicine. 2017;96:e8070.

Wang T, Jiang M, Ren Y, Liu Q, Zhao G, Cao C, et al. Health-related quality of life of community thyroid cancer survivors in Hangzhou, China. Thyroid. 2018;28:1013-23.

Li J, Zhang B, Bai Y, Liu Y, Zhang B, Jin J. Health-re-lated quality of life analysis in differentiated thy-roid carcinoma patients after thyroidectomy. Sci Rep-UK. 2020;10:1-7.

Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S, et al. The impact of thyroid cancer and post-surgical radioactive iodine treat-ment on the lives of thyroid cancer survivors: a qualitative study. PloS One. 2009;4:e4191.

Gamper E-M, Wintner LM, Rodrigues M, Buxbaum S, Nilica B, Singer S, et al. Persistent quality of life impairments in differentiated thyroid cancer pa-tients: results from a monitoring programme. Eur J Nucl Med Mol I. 2015;42:1179-88.

Rubic M, Kuna SK, Tesic V, Samardzic T, Despot M, Huic D. The most common factors influencing on quality of life of thyroid cancer patients after thy-roid hormone withdrawal. Psychiatr Danub. 2014; 26:520-27.

Husson O, Nieuwlaat WA, Oranje WA, Haak HR, van de Poll-Franse LV, Mols F. Fatigue among short-and long-term thyroid cancer survivors: results from the population-based PROFILES registry. Thyroid. 2013;23:1247-55.

Narayanan V, and Koshy C. Fatigue in cancer: a re-view of literature. Indian J Palliat Care. 2009;15:19-25.

Lan Y, Luo Y, Zhang M, Jin Z, Xiao J, Yan L, et al. Quality of life in papillary thyroid microcarcino-ma patients undergoing radiofrequency ablation or surgery: a comparative study. Front Endocrinol. 2020;11:249.

Kaltsas G, Vgontzas A, Chrousos G. Fatigue, endo-crinopathies, and metabolic disorders. PM R. 2010; 2:393-98.

Carroll DL, Hamilton GA, McGovern BA. Changes in health status and quality of life and the impact of uncertainty in patients who survive life-threat-ening arrhythmias. Heart Lung. 1999;28:251-60.

Crevenna R, Zettinige G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in pa-tients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. Support Care Cancer. 2003;11:597–603.

Ritter K, Elfenbein D, Schneider DF, Chen H, Sip-pel RS. Hypoparathyroidism after total thyroidec-tomy: incidence and resolution. J Surg Res. 2015; 197:348-53.

Sörqvist P, Dahlström Ö, Karlsson T, Rönnberg J. Concentration: the neural underpinnings of how cognitive load shields against distraction. Front Hum Neurosci. 2016;10:221.

Hu Y, Lei X, Smith JP, Zhao Y. Effects of social activities on cognitive functions: Evidence from CHARLS. In: Smith JP, Majmundar M, editors. Aging in Asia: Findings From New and Emerging Data Initiatives. Washington (DC): National Acad-emies Press (US); 2012; p. 918.

Vigário PdS, Chachamovitz DSdO, Teixeira PdFdS, Rocque MdL, Santos MLd, Vaisman M. Exercise is associated with better quality of life in patients on TSH-suppressive therapy with levothyroxine for differentiated thyroid carcinoma. Arq Bras Endo-crinol. 2014;58:274-81.

Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health-related quality of life in thyroid cancer survivors. Laryngoscope. 2007;117:507-10.

Sung TY, Shin YW, Nam KH, Chang HS, Rhee Y, Park CS, et al. Psychological impact of thyroid sur-gery on patients with well-differentiated papillary thyroid cancer. Qual Life Res. 2011;20:1411-17.

Goswami S, Mongelli M, Peipert BJ, Helenowski I, Yount SE, Sturgeon C. Benchmarking health-re-lated quality of life in thyroid cancer versus other cancers and United States normative data. Sur-gery. 2018;164:986-92